ConductScience.org, home

Paper20065327

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Howden BP and 4 others. Clin Microbiol Rev, 2010. Cited by 713 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Papers, record 20065327. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20065327

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.
PubMed
Journal
Clin Microbiol Rev
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
713
iCite
Relative citation ratio, by iCite
23.8
iCite
Revised in PubMed
2024-11-05
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Howden BPBenjamin P
2Davies JKJohn K
3Johnson PDPaul D R
4Stinear TPTimothy P
5Grayson MLM Lindsay

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Staphylococcal InfectionsMajor topic
Staphylococcus aureusMajor topic
VancomycinMajor topic
Vancomycin ResistanceMajor topic
Humans
Microbial Sensitivity Tests
Treatment Outcome

Source PubMed

References389

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111,118,389Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.Clin Infect Dis2001https://conductscience.org/library/papers/11118389PubMed
217,355,211Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Expert Opin Emerg Drugs2007https://conductscience.org/library/papers/17355211PubMed
310,085,071Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides.J Biol Chem1999https://conductscience.org/library/papers/10085071PubMed
415,000,746
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Microb Drug Resist2003https://conductscience.org/library/papers/15000746PubMed
510,639,349Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.Antimicrob Agents Chemother2000https://conductscience.org/library/papers/10639349PubMed
614,742,221Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains.Antimicrob Agents Chemother2004https://conductscience.org/library/papers/14742221PubMed
712,672,861Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.N Engl J Med2003https://conductscience.org/library/papers/12672861PubMed
819,420,170Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.J Clin Microbiol2009https://conductscience.org/library/papers/19420170PubMed
911,073,773An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital.Clin Infect Dis2000https://conductscience.org/library/papers/11073773PubMed
1015,682,283Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.Eur J Clin Microbiol Infect Dis2005https://conductscience.org/library/papers/15682283PubMed
119,249,217Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.J Antimicrob Chemother1997https://conductscience.org/library/papers/9249217PubMed
1217,418,637Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus.Int J Med Microbiol2007https://conductscience.org/library/papers/17418637PubMed
1316,436,693Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16436693PubMed
1412,791,129Autoinduction and signal transduction in the regulation of staphylococcal virulence.Mol Microbiol2003https://conductscience.org/library/papers/12791129PubMed
158,569,574Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR).Med J Aust1996https://conductscience.org/library/papers/8569574PubMed
1610,321,654Staphylococcus aureus infections in trauma patients.Crit Care Med1999https://conductscience.org/library/papers/10321654PubMed
1710,021,469Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.N Engl J Med1999https://conductscience.org/library/papers/10021469PubMed
1815,555,885Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study.Int J Antimicrob Agents2004https://conductscience.org/library/papers/15555885PubMed
1910,589,883Bacteremia caused by staphylococci with inducible vancomycin heteroresistance.Clin Infect Dis1999https://conductscience.org/library/papers/10589883PubMed
2011,427,551Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.J Clin Microbiol2001https://conductscience.org/library/papers/11427551PubMed

See all 389 references

Cited by436

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 713 citations.

PMIDTitleJournalYearIn PapersSource
42,852,299Design, Synthesis, and Microbiological Evaluation of Differently Decorated Pyrazoles Able to Overcome Antimicrobial Resistance and Biofilm Formation.ACS Omega2026https://conductscience.org/library/papers/42852299PubMed
42,795,533Epidemiology of Infections Caused by Gram-Positive Cocci-Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecium: Antibiotic Resistance and Future Prospects.Microorganisms2026https://conductscience.org/library/papers/42795533PubMed
42,747,188Prophage and metabolic determinants of Staphylococcus aureus survival to vancomycin identified via TraDIS screening.mSystems2026https://conductscience.org/library/papers/42747188PubMed
42,688,403Zanthoxylum beecheyanum enhances vancomycin activity and inhibits biofilm formation in resistant staphylococcus aureus.Front Pharmacol2026https://conductscience.org/library/papers/42688403PubMed
42,555,848Assessing Vancomycin-Formyl Peptide Conjugate Binding to the Surface of Resistant Staphylococcus aureus via Flow Cytometry.Chembiochem2026https://conductscience.org/library/papers/42555848PubMed
42,539,783Global trends and research profile of antibiotic heteroresistance: a bibliometric and visual analysis.Front Microbiol2026https://conductscience.org/library/papers/42539783PubMed
42,505,673Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States.Antibiotics (Basel)2026https://conductscience.org/library/papers/42505673PubMed
42,504,701The efflux pump QacA mediates the transition to vancomycin heteroresistance in sequence type 5 methicillin-resistant Staphylococcus aureus via membrane lipid reprogramming.Emerg Microbes Infect2026https://conductscience.org/library/papers/42504701PubMed
42,422,740Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus.Front Microbiol2026https://conductscience.org/library/papers/42422740PubMed
42,397,472Beyond susceptibility results: understanding the clinical and diagnostic burden of bacterial heteroresistance.Mol Biol Rep2026https://conductscience.org/library/papers/42397472PubMed
42,281,686Staphylococcus aureus With Reduced Vancomycin Susceptibility: Diagnostic Challenges in Clinical Settings.Cureus2026https://conductscience.org/library/papers/42281686PubMed
42,251,270
The global scope of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA): a meta-analysis of its clinical impact, molecular epidemiology, and diagnostic challenges across 15,165 isolates.
BMC Infect Dis2026https://conductscience.org/library/papers/42251270PubMed
42,235,930Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus.J Antimicrob Chemother2026https://conductscience.org/library/papers/42235930PubMed
42,148,584Four-year antibiogram analysis of priority pathogens: guiding empirical therapy and monitoring resistance trends.Microbiol Spectr2026https://conductscience.org/library/papers/42148584PubMed
42,059,658LYSG101: a potent chimeric lysin with therapeutic potential for combating Staphylococcus aureus infections.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42059658PubMed
41,982,279Risk Factors Associated With Methicillin-Resistant Staphylococcus aureus Infections in Patients With Diabetic Foot Ulcers in Tehran.Can J Infect Dis Med Microbiol2026https://conductscience.org/library/papers/41982279PubMed
41,971,396Vancomycin MIC creep and the emergence of oxacillin-susceptible MRSA: A three-year surveillance study from a tertiary care centre.New Microbes New Infect2026https://conductscience.org/library/papers/41971396PubMed
41,931,187Green one pot synthesis of silver nanoparticles for antioxidant and antimicrobial activities.Discov Nano2026https://conductscience.org/library/papers/41931187PubMed
41,822,371Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil.Open Forum Infect Dis2026https://conductscience.org/library/papers/41822371PubMed
41,753,631Beyond Antibiotics: Therapeutic Strategies Utilizing Probiotics and Bacteriophages Against Drug-Resistant Staphylococcus aureus.Microorganisms2026https://conductscience.org/library/papers/41753631PubMed

See all 436 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20065327

GET https://conductscience.org/api/papers/v1/20065327/references?page=2